Can you detail the characteristics of the cohorts studied in the LEADER Trial? What percentage of patients was evaluated for primary prevention vs. secondary prevention of CV events?

Can you detail the characteristics of the cohorts studied in the LEADER Trial? What percentage of patients was evaluated for primary prevention vs. secondary prevention of CV events?

Can you detail the background characteristics of the patient cohorts studied in the LEADER Trial? What percentage of patients was evaluated for primary prevention vs. secondary prevention of cardiovascular events?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Josep Vidal, MD, PhD

Josep Vidal, MD, PhD

Obesity Unit, Endocrinology and Diabetes Unit
University Hospital Clinic
Barcelona, Spain